Back to search results

Inhaled Cromolyn Sodium for Locally Advanced Lung Cancer

This study is looking at inhaled cromolyn sodium for people with locally advanced non-small cell lung cancer or lung adenocarcinoma. Cromolyn sodium is a medication already approved for other breathing problems. Researchers want to see if this drug, which helps stabilize mast cells (a type of immune cell), can be safe and well-tolerated in lung cancer patients. They are also looking for early signs that it might help by affecting how tumors grow and interact with the immune system. The study plans to enroll 10 participants and will check for safety and how well people tolerate the treatment for up to 12 months.

Study design
This is an open-label pilot study, meaning both you and the study team will know you are receiving cromolyn sodium. It plans to include 10 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for safety and tolerability for up to 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07675876

Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer

Not Yet Recruiting
PHASE1Ages 18+InterventionalTreatment
Carcinex Inc
~10 participants
Updated 2026-07-01 on ClinicalTrials.gov
What's tested:Cromolyn Sodium

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and Tolerability of Inhaled Cromolyn Sodium
Measured over Up to 12 months

Conditions

Locally Advanced Non-Small Cell Lung Cancer
Lung Adenocarcinoma

Explore related trials

Lung AdenocarcinomaLung Non-Small Cell Carcinoma

Where it's being run

2 sites across 1 states
Colorado2

Study leadership

  • Charles Owen · STUDY_DIRECTOR · Carcinex Inc

Who to contact

Svitlana Nesterenko, AGCP-Nurse Practitioner
[email protected]
7204721934
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Provide written informed consent prior to screening.
Male or female patients, age ≥ 18 years
Histological- or cytological-confirmed diagnosis of Lung cancer
Previous tumor scan location in lung

Exclusion

Treatment with another investigational drug, biological agent, or device within 4 weeks (6 weeks for biological agents) before screening or 5 half-lives of study agent, whichever is longer.
Patients with known pericardial effusion
Patients with active infection or serious concomitant systemic disorder (for example, heart failure) incompatible with the study (at the discretion of the Investigator)
Planned concomitant participation in another clinical trial of an experimental agent, vaccine, or device.
Patients with any other medical condition that in the opinion of the Investigator would make the patient unsuitable for enrollment, or could interfere with the patient participating in or completing the study.
Known allergy or history of serious adverse event with Cromolyn Sodium

What this trial measures

  • Safety and Tolerability of Inhaled Cromolyn SodiumUp to 12 months

    Incidence, severity, and frequency of treatment-emergent adverse events and serious adverse events during study participation.